Investigational Drug Information for Albaconazole
✉ Email this page to a colleague
What is the development status for investigational drug Albaconazole?
Albaconazole is an investigational drug.
There have been 6 clinical trials for Albaconazole.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2004.
The most common disease conditions in clinical trials are Onychomycosis, Tinea, and Vulvovaginitis. The leading clinical trial sponsors are GlaxoSmithKline, Stiefel, a GSK Company, and J. Uriach and Company.
Summary for Albaconazole
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 412 |
| WIPO Patent Applications | 338 |
| Japanese Patent Applications | 84 |
| Clinical Trial Progress | Phase 2 (2004-06-01) |
| Vendors | 37 |
Recent Clinical Trials for Albaconazole
| Title | Sponsor | Phase |
|---|---|---|
| Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease | Eisai Co., Ltd. | Phase 2 |
| Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease | Drugs for Neglected Diseases | Phase 2 |
| A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule | GlaxoSmithKline | Phase 1 |
Clinical Trial Summary for Albaconazole
Top disease conditions for Albaconazole
Top clinical trial sponsors for Albaconazole
US Patents for Albaconazole
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
